Top Markets
Coin of the day
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
Rangering i aksjer #19170
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Aksjekurs
$1.62
Sist synkronisert: 2026-08-25
Markedsverdi
$172.47M
Endring (1 dag)
-3.57%
Endring (1 år)
446.74%
Land
US
Handel Cypherpunk Technologies Inc. (CYPH)

Kategori

P/S-forhold for Cypherpunk Technologies Inc. (CYPH)
P/S-forhold per 2026 TTM: 0
Ifølge Cypherpunk Technologies Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Cypherpunk Technologies Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH